SENORES PHARMACEUTICALS L SENORES NSEPHARMA
Company Overview
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
Why Investors Should Care
Return on capital employed stands at 15.6%.
Net profit has compounded at 139.2% per year over the last five years.
Revenue has grown at a 161.6% CAGR over the past five years.
Maintains a net profit margin of 18.2%.
Carries low leverage with a debt-to-equity ratio of 0.37.
Recent Developments
- Mar 2026 Revenue of ₹632.63 Cr (+58.9% YoY); net profit ₹115.38 Cr.
- Trailing 12 Months Year-on-year growth — revenue +58.9%, earnings +97.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 161.6%, profit CAGR 139.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 161.63% |
| 1 Year: | 58.85% |
Compounded Profit Growth
| 5 Years: | 139.18% |
| 1 Year: | 97.00% |
Stock Price Performance
| 1 Year: | +149.64% |
| 6 Months: | +80.91% |
| 3 Months: | +64.88% |
| 1 Month: | +14.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)77.32 · Overbought
P/E of 55.62 is above the sector median of 39.97 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 161.6% over 5 years.
- Profit CAGR of 139.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 55.6.
- RSI at 77 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SENORES SENORES PHARMACEUTICALS L NSEPHARMA | 1,467.90 | 55.62 | ₹6,760.21 Cr | 0.00% | 15.61% | 12.36% | 161.63% | 139.18% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 79.00 Cr | 102.00 Cr | 80.00 Cr | 101.00 Cr | - | 114.21 Cr | 130.30 Cr | 153.36 Cr | 164.85 Cr | 175.19 Cr |
| Cost of Revenue | - | - | - | - | - | 57.46 Cr | 61.36 Cr | 57.08 Cr | 67.02 Cr | 66.22 Cr |
| Gross Profit | - | - | - | - | - | 56.75 Cr | 68.94 Cr | 96.28 Cr | 97.83 Cr | 108.97 Cr |
| Operating Expenses | 64.00 Cr | 80.00 Cr | 59.00 Cr | 77.00 Cr | - | 42.54 Cr | 40.76 Cr | 54.87 Cr | 51.70 Cr | 70.78 Cr |
| Operating Income | 12.00 Cr | 18.00 Cr | 17.00 Cr | 19.00 Cr | - | 14.21 Cr | 28.18 Cr | 41.41 Cr | 46.13 Cr | 38.19 Cr |
| EBITDA | 15.00 Cr | 22.00 Cr | 21.00 Cr | 23.00 Cr | - | 31.21 Cr | 37.52 Cr | 54.92 Cr | 57.79 Cr | 65.16 Cr |
| Interest Expense | 2.00 Cr | 3.00 Cr | 5.00 Cr | 5.00 Cr | - | 5.30 Cr | 5.04 Cr | 6.19 Cr | 5.33 Cr | 8.46 Cr |
| Pretax Income | 10.00 Cr | 18.00 Cr | 13.00 Cr | 16.00 Cr | - | 20.68 Cr | 26.49 Cr | 40.64 Cr | 44.60 Cr | 47.40 Cr |
| Tax Provision | 3.10 Cr | 3.42 Cr | 2.47 Cr | 2.88 Cr | - | 2.71 Cr | 5.31 Cr | 10.51 Cr | 11.02 Cr | 10.73 Cr |
| Net Income | 7.00 Cr | 14.00 Cr | 11.00 Cr | 13.00 Cr | - | 17.83 Cr | 19.73 Cr | 32.38 Cr | 31.66 Cr | 31.61 Cr |
| Diluted EPS | 2.37 | 5.23 | 3.23 | 3.86 | - | 3.81 | 4.60 | 6.54 | 7.29 | 7.96 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 35.33 Cr | 210.78 Cr | 398.25 Cr | 632.63 Cr |
| Cost of Revenue | - | 12.77 Cr | 111.17 Cr | 180.70 Cr | 251.66 Cr |
| Gross Profit | - | 22.56 Cr | 99.61 Cr | 217.55 Cr | 380.97 Cr |
| Operating Expenses | - | 11.67 Cr | 67.87 Cr | 144.69 Cr | 243.90 Cr |
| Operating Income | - | 10.89 Cr | 31.74 Cr | 72.86 Cr | 137.07 Cr |
| EBITDA | - | 16.05 Cr | 43.46 Cr | 108.96 Cr | 215.38 Cr |
| Interest Expense | - | 1.84 Cr | 8.50 Cr | 21.55 Cr | 25.03 Cr |
| Pretax Income | - | 12.44 Cr | 24.94 Cr | 70.57 Cr | 159.10 Cr |
| Tax Provision | - | 4.00 Cr | -7.76 Cr | 12.23 Cr | 37.57 Cr |
| Net Income | - | 8.43 Cr | 31.45 Cr | 58.57 Cr | 115.38 Cr |
| Diluted EPS | - | 1.83 | 6.83 | 16.12 | 26.39 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 131.05 Cr | 621.88 Cr | 1,226.86 Cr | 1,603.81 Cr |
| Current Assets | - | 51.34 Cr | 250.91 Cr | 722.43 Cr | 812.43 Cr |
| Cash & Equivalents | - | 10.00 L | 7.65 Cr | 105.38 Cr | 45.55 Cr |
| Inventory | - | 3.12 Cr | 37.37 Cr | 56.63 Cr | 89.29 Cr |
| Receivables | - | 22.11 Cr | 112.01 Cr | 123.88 Cr | 324.82 Cr |
| Total Liabilities | - | 85.55 Cr | 390.17 Cr | 414.61 Cr | 639.27 Cr |
| Current Liabilities | - | 51.88 Cr | 247.50 Cr | 240.70 Cr | 424.00 Cr |
| Long Term Debt | - | 29.73 Cr | 133.65 Cr | 162.46 Cr | 194.89 Cr |
| Total Debt | - | 62.59 Cr | 257.64 Cr | 314.75 Cr | 342.03 Cr |
| Total Equity | - | 45.50 Cr | 204.27 Cr | 786.19 Cr | 933.60 Cr |
| Shares Outstanding | - | 4.61 Cr | 4.61 Cr | 4.61 Cr | 4.61 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.08 Cr | -25.70 Cr | -45.92 Cr | 62.05 Cr |
| Investing Cash Flow | - | -48.29 Cr | -54.23 Cr | -429.48 Cr | -120.56 Cr |
| Financing Cash Flow | - | 46.25 Cr | 86.98 Cr | 573.13 Cr | -1.33 Cr |
| Capital Expenditure | - | -47.28 Cr | -51.83 Cr | -157.52 Cr | -264.73 Cr |
| Free Cash Flow | - | -48.36 Cr | -77.53 Cr | -203.44 Cr | -202.68 Cr |
| Net Change in Cash | - | -3.12 Cr | 7.05 Cr | 97.73 Cr | -59.84 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 63.9% | 47.3% | 54.6% | 60.2% |
| Operating Margin % | - | 30.8% | 15.1% | 18.3% | 21.7% |
| Net Margin % | - | 23.9% | 14.9% | 14.7% | 18.2% |
| ROE % | - | 18.5% | 15.4% | 7.4% | 12.4% |
| ROCE % | - | 13.8% | 8.5% | 7.4% | 11.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SENORES
Senores Pharmaceuticals' (NSE:SENORES) Solid Profits Have Weak Fundamentals - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxORXhmcS1za29hMWw1Z0ZxV1NJcURtelpkQjNyUmRqQXVyX1QyUUdXYlRsY1V4dzJiZk9fWmppVjlMaGl5NENIdFVTLUEzM3dUVFpwSEh2eVVON3BvM2xCQ1BaeEhzX0REVmU0V3NwM3pPT0gwRWQ5U0hyOTJJZHptWEpIeDgwOE9YWWpYc0…
9,233,746 Equity Shares of Senores Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 27-JUN-2026. - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVFJUZHl3dUhaUGk5bmxBb0xKWTBrVThablVnZS1jdG5qU25TUlU0d0hJbVVYY0ZVay0xc1lfOW1KNklzX0M3aW1KWHJ5Wl9Ud2VDMGE4cG50a2I0UHNBUWp0N3lBRkJqMUpka0gxMDRsVi1QYmR5UFd5cmVOeUlkY3dnMjFvUzBVTy10RT…
Buy Senores Pharma; target of Rs 1640: Choice Institutional Equities - Moneycontrol.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNZDhGNm9RSmRsRUFNb3RvQXlubjY4Y2I1ZXQxeFR3bG1uRmxIdHhkZnFCQWhjVExzZ0Y4R0h5cFZUNmFxVklMSHQxSm8wTmIyZjBibXdCMUVZWXI2Sm9rTlA4aDJyZFF4c2ZPVFdza2RzNHp4Zk8zb1pYRXppVWF0UmZ0b1pGMWZZTTNtQ0…
Technical Stock Calls: Kush Bohra's Buy Calls, Target Price, Stop Loss — Senores Pharma And More - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQNUQwWnZqM3V0WXNoQ2NHOFdKU0xtOXhEVzNkc3h0WmhoQ3pyRUQzal9VeThIODgtdWQzajNQdEdGVnMySngzS2dJa2piTllQaHllMktOQzlCVGs5OHZTVHFDeC00YXR1czI4Qld5OHlxZ1lOSFp3Z2FJUUdsOUVRMzJXQ29TMlVUUGdXbk…
Senores Pharmaceuticals - 5 stocks bought by FIIs, MFs and retail investors rally up to 60% in 6 months - The Economic Times
<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxOWGtvdmdXVzg5WEYwVUtqT3dKeFZ2T1cxMGlzMWlEM1dPdUM2akFIXzdCUlFfd1VieVZycTJpR05fLUpDY0Q0cXVvYVIxcFJTWkM0QjdnTmxON3VMcXB0VzlIbkhNNDdrUkxfdG9iZHg4cWtTaEdTcGtBVzNiY1M0ci1Fam8weEZyRnhqYW…
Senores Pharma Targets 60% Profit Surge in FY27 Amid 40% Revenue Growth Outlook - Sahi
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPZUV6VFZWYXVoN25ra1hlclBqUUczTEVHc1JEU1E5dHJtcUtoTnZmT0hmcUNfWENoUlZreWlSemk3a2hEaFAtWU9lUzVkNzI1dndiMy1OTGRrLThfRTRPendQTUkxcDM0bUZIeU5FckNvNTgtelJqYkVyVVNFRDZZcTh3RG9RTi11ZzM5Sn…
SENORES — Frequently Asked Questions
What is the current share price of SENORES PHARMACEUTICALS L (SENORES)?
As of 2026-07-15 09:52 IST, SENORES PHARMACEUTICALS L (SENORES) trades at ₹1,467.90 on NSE. Its 52-week range is ₹588.00 to ₹1,467.90.
What is the market capitalisation of SENORES?
SENORES PHARMACEUTICALS L (SENORES) has a market capitalisation of ₹6,760.21 Cr on NSE.
What is the P/E ratio of SENORES?
SENORES trades at a trailing price-to-earnings (P/E) ratio of 55.62. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 6.11.
What is the return on equity (ROE) of SENORES?
SENORES has a return on equity (ROE) of 12.36%. Its return on capital employed (ROCE) is 15.61%.
Is SENORES a good stock to buy?
This page provides a data-driven analysis of SENORES PHARMACEUTICALS L (SENORES), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.